These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28926422)

  • 1. Two faces of Hippo: activate or suppress the Hippo pathway in cancer.
    Cao J; Huang W
    Anticancer Drugs; 2017 Nov; 28(10):1079-1085. PubMed ID: 28926422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hippo-YAP signaling pathway: A new paradigm for cancer therapy.
    Ma Y; Yang Y; Wang F; Wei Q; Qin H
    Int J Cancer; 2015 Nov; 137(10):2275-86. PubMed ID: 25042563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment.
    Santucci M; Vignudelli T; Ferrari S; Mor M; Scalvini L; Bolognesi ML; Uliassi E; Costi MP
    J Med Chem; 2015 Jun; 58(12):4857-73. PubMed ID: 25719868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Furry protein suppresses nuclear localization of yes-associated protein (YAP) by activating NDR kinase and binding to YAP.
    Irie K; Nagai T; Mizuno K
    J Biol Chem; 2020 Mar; 295(10):3017-3028. PubMed ID: 31996378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting YAP and Hippo signaling pathway in liver cancer.
    Liu AM; Xu MZ; Chen J; Poon RT; Luk JM
    Expert Opin Ther Targets; 2010 Aug; 14(8):855-68. PubMed ID: 20545481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression.
    He C; Mao D; Hua G; Lv X; Chen X; Angeletti PC; Dong J; Remmenga SW; Rodabaugh KJ; Zhou J; Lambert PF; Yang P; Davis JS; Wang C
    EMBO Mol Med; 2015 Nov; 7(11):1426-49. PubMed ID: 26417066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Role of a C-Terminally Truncated Isoform of Large Tumor Suppressor Kinase 1 in the Regulation of Hippo Signaling and Tissue Growth.
    Matsui Y; Zhang Y; Paulson RF; Lai ZC
    DNA Cell Biol; 2019 Jan; 38(1):91-106. PubMed ID: 30461308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hippo signaling dysfunction induces cancer cell addiction to YAP.
    Han H; Yang B; Nakaoka HJ; Yang J; Zhao Y; Le Nguyen K; Bishara AT; Mandalia TK; Wang W
    Oncogene; 2018 Dec; 37(50):6414-6424. PubMed ID: 30068939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-Catenin destruction complex-independent regulation of Hippo-YAP signaling by APC in intestinal tumorigenesis.
    Cai J; Maitra A; Anders RA; Taketo MM; Pan D
    Genes Dev; 2015 Jul; 29(14):1493-506. PubMed ID: 26193883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Hippo/YAP in intrahepatic cholangiocarcinoma: Promising molecules in cancer therapy.
    Ma X; Zhou Y; Li R; Ding X; Li D; Pan T; Zhang F; Li W
    Mol Carcinog; 2024 Oct; 63(10):1866-1873. PubMed ID: 39092765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of Proliferation and Cancer Growth by the Hippo Signaling Pathway.
    Ehmer U; Sage J
    Mol Cancer Res; 2016 Feb; 14(2):127-40. PubMed ID: 26432795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the Hippo pathway: Clinical implications and therapeutics.
    Ye S; Eisinger-Mathason TS
    Pharmacol Res; 2016 Jan; 103():270-8. PubMed ID: 26678601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evolutionarily conserved negative feedback mechanism in the Hippo pathway reflects functional difference between LATS1 and LATS2.
    Park GS; Oh H; Kim M; Kim T; Johnson RL; Irvine KD; Lim DS
    Oncotarget; 2016 Apr; 7(17):24063-75. PubMed ID: 27006470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling.
    Yu FX; Zhao B; Panupinthu N; Jewell JL; Lian I; Wang LH; Zhao J; Yuan H; Tumaneng K; Li H; Fu XD; Mills GB; Guan KL
    Cell; 2012 Aug; 150(4):780-91. PubMed ID: 22863277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Hippo pathway member Nf2 is required for inner cell mass specification.
    Cockburn K; Biechele S; Garner J; Rossant J
    Curr Biol; 2013 Jul; 23(13):1195-201. PubMed ID: 23791728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of the Hippo-YAP pathway in multiple cancer contexts.
    Kim HB; Myung SJ
    BMB Rep; 2018 Mar; 51(3):119-125. PubMed ID: 29366445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The phosphoinositide PI5P inhibits the Hippo pathway effector YAP.
    Baumann K
    Nat Rev Mol Cell Biol; 2024 Jul; 25(7):513. PubMed ID: 38858473
    [No Abstract]   [Full Text] [Related]  

  • 18. Crosstalk between Hippo signalling and miRNAs in tumour progression.
    Li N; Xie C; Lu N
    FEBS J; 2017 Apr; 284(7):1045-1055. PubMed ID: 27973704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TEAD1 mediates the oncogenic activities of Hippo-YAP1 signaling in osteosarcoma.
    Chai J; Xu S; Guo F
    Biochem Biophys Res Commun; 2017 Jun; 488(2):297-302. PubMed ID: 28483529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ.
    Yi J; Lu L; Yanger K; Wang W; Sohn BH; Stanger BZ; Zhang M; Martin JF; Ajani JA; Chen J; Lee JS; Song S; Johnson RL
    Hepatology; 2016 Nov; 64(5):1757-1772. PubMed ID: 27531557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.